Shareholder Alert: Ademi LLP Investigates Whether Taro Pharmaceutical Industries Limited Has Obtained a Fair Price for Its Public Shareholders in Its Transaction With Its Majority Shareholder, Sun Pharmaceutical Industries Limited.

PR Newswire · May 21 03:10

MILWAUKEE, May 20, 2024 /PRNewswire/ -- Ademi LLP is investigating Taro (NYSE: TARO) for possible breaches of fiduciary duty and other violations of law in its transaction with its majority shareholder Sun.

Click here to learn how to join the or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

In the transaction, Taro's stockholders receive $43.00 in cash for each share of Taro common stock they own. Taro insiders receive substantial benefits as part of change of control arrangements and Taro's board is not likely to have been independent in its negotiation of the transaction given Sun's majority position.

We are investigating the conduct of Taro's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Taro common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

Shareholder Alert: Ademi LLP Investigates Whether Taro Pharmaceutical Industries Limited Has Obtained a Fair Price for Its Public Shareholders in Its Transaction With Its Majority Shareholder, Sun Pharmaceutical Industries Limited.

Risk Disclaimer